Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene RET
Variant E632_L633del
Impact List deletion
Protein Effect gain of function - predicted
Gene Variant Descriptions RET E632_L633del results in the deletion of two amino acids in the cysteine-rich region of the Ret protein from amino acids 632 to 633 (PMID: 9879991). E632_L633del is transforming in cell culture (PMID: 9191060), and therefore, is predicted to lead to a gain of Ret protein function.
Associated Drug Resistance
Category Variants Paths

RET mutant RET act mut RET E632_L633del

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_020975.6
gDNA chr10:g.43114494_43114499delGAGCTG
cDNA c.1894_1899delGAGCTG
Protein p.E632_L633delEL
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001406778.1 chr10:g.43120094_43120099delACTTGG c.1895_1900delACTTGG p.D632_L633delDL RefSeq GRCh38/hg38
NM_001406759.1 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001406774.1 chr10:g.43119557_43119562delGCCAAA c.1894_1899delGCCAAA p.A632_K633delAK RefSeq GRCh38/hg38
NM_001355216.1 chr10:g.43120129_43120134delCGGAAG c.1894_1899delCGGAAG p.R632_K633delRK RefSeq GRCh38/hg38
NM_001406768.1 chr10:g.43116605_43116610delCCTCGG c.1894_1899delCCTCGG p.P632_R633delPR RefSeq GRCh38/hg38
NM_001406791.1 chr10:g.43126734_43126739delCATGCA c.1894_1899delCATGCA p.H632_A633delHA RefSeq GRCh38/hg38
NM_001406769.1 chr10:g.43118378_43118383delGCCTCC c.1894_1899delGCCTCC p.A632_S633delAS RefSeq GRCh38/hg38
NM_001406776.1 chr10:g.43120094_43120099delACTTGG c.1895_1900delACTTGG p.D632_L633delDL RefSeq GRCh38/hg38
NM_020975.6 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001406744.1 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001406780.1 chr10:g.43122006_43122011delCAAAGT c.1894_1899delCAAAGT p.Q632_S633delQS RefSeq GRCh38/hg38
NM_020630.7 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001406779.1 chr10:g.43122006_43122011delCAAAGT c.1894_1899delCAAAGT p.Q632_S633delQS RefSeq GRCh38/hg38
NM_001406781.1 chr10:g.43122006_43122011delCAAAGT c.1894_1899delCAAAGT p.Q632_S633delQS RefSeq GRCh38/hg38
NM_001406777.1 chr10:g.43120094_43120099delACTTGG c.1895_1900delACTTGG p.D632_L633delDL RefSeq GRCh38/hg38
NM_001406771.1 chr10:g.43118420_43118425delGTCCTG c.1894_1899delGTCCTG p.V632_L633delVL RefSeq GRCh38/hg38
NM_001406785.1 chr10:g.43123780_43123785delGAGAGG c.1894_1899delGAGAGG p.E632_R633delER RefSeq GRCh38/hg38
NM_001406766.1 chr10:g.43116629_43116634delAAAACT c.1894_1899delAAAACT p.K632_T633delKT RefSeq GRCh38/hg38
NM_001406772.1 chr10:g.43118378_43118383delGCCTCC c.1894_1899delGCCTCC p.A632_S633delAS RefSeq GRCh38/hg38
NM_001406788.1 chr10:g.43126614_43126619delCTGATT c.1894_1899delCTGATT p.L632_I633delLI RefSeq GRCh38/hg38
NM_001406787.1 chr10:g.43123795_43123800delTGCAGC c.1894_1899delTGCAGC p.C632_S633delCS RefSeq GRCh38/hg38
NM_001406770.1 chr10:g.43116629_43116634delAAAACT c.1894_1899delAAAACT p.K632_T633delKT RefSeq GRCh38/hg38
NM_001406763.1 chr10:g.43114630_43114635delGGAGGC c.1895_1900delGGAGGC p.R632_R633delRR RefSeq GRCh38/hg38
NM_001406767.1 chr10:g.43116629_43116634delAAAACT c.1894_1899delAAAACT p.K632_T633delKT RefSeq GRCh38/hg38
NM_001406775.1 chr10:g.43120094_43120099delACTTGG c.1895_1900delACTTGG p.D632_L633delDL RefSeq GRCh38/hg38
NM_001406764.1 chr10:g.43114623_43114628delACCTTC c.1894_1899delACCTTC p.T632_F633delTF RefSeq GRCh38/hg38
NM_001406789.1 chr10:g.43126614_43126619delCTGATT c.1894_1899delCTGATT p.L632_I633delLI RefSeq GRCh38/hg38
NM_001406782.1 chr10:g.43122006_43122011delCAAAGT c.1894_1899delCAAAGT p.Q632_S633delQS RefSeq GRCh38/hg38
NM_020975 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001406783.1 chr10:g.43123789_43123794delGACAAC c.1894_1899delGACAAC p.D632_N633delDN RefSeq GRCh38/hg38
NM_020630 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001406760.1 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001406762.1 chr10:g.43114623_43114628delACCTTC c.1894_1899delACCTTC p.T632_F633delTF RefSeq GRCh38/hg38
NM_001406743.1 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001406761.1 chr10:g.43114623_43114628delACCTTC c.1894_1899delACCTTC p.T632_F633delTF RefSeq GRCh38/hg38
NM_020975.5 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_020630.5 chr10:g.43114494_43114499delGAGCTG c.1894_1899delGAGCTG p.E632_L633delEL RefSeq GRCh38/hg38
NM_001355216.2 chr10:g.43120129_43120134delCGGAAG c.1894_1899delCGGAAG p.R632_K633delRK RefSeq GRCh38/hg38
NM_001406790.1 chr10:g.43126614_43126619delCTGATT c.1894_1899delCTGATT p.L632_I633delLI RefSeq GRCh38/hg38
NM_001406773.1 chr10:g.43118420_43118425delGTCCTG c.1894_1899delGTCCTG p.V632_L633delVL RefSeq GRCh38/hg38
NM_001406765.1 chr10:g.43114630_43114635delGGAGGC c.1895_1900delGGAGGC p.R632_R633delRR RefSeq GRCh38/hg38
NM_001406784.1 chr10:g.43123753_43123758delAACCTT c.1894_1899delAACCTT p.N632_L633delNL RefSeq GRCh38/hg38
NM_001406786.1 chr10:g.43123789_43123794delGACAAC c.1894_1899delGACAAC p.D632_N633delDN RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET act mut lung non-small cell carcinoma sensitive Ponatinib Preclinical - Cell culture Actionable In a preclinical study, Iclusig (ponatinib) inhibited RET phosphorylation and reduced viability of non-small cell lung cancer cells with RET activating mutations (Cancer Res April 15, 2013 73; 2084). detail...
RET mutant thyroid gland medullary carcinoma sensitive Selpercatinib FDA approved - Has Companion Diagnostic Actionable In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55), with five complete and 33 partial responses, in adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations who were previously treated, while patients who had not been previously treated demonstrated an ORR of 73% (64/88), with ten complete and 54 partial responses (PMID: 32846061; NCT03157128). detail... detail... 32846061
RET mutant thyroid gland medullary carcinoma sensitive Selpercatinib Guideline Actionable Retevmo (selpercatinib) is included in guidelines for patients with medullary thyroid carcinoma harboring RET mutations (NCCN.org). detail...
RET mutant thyroid gland medullary carcinoma sensitive Selpercatinib FDA approved - Has Companion Diagnostic Actionable In a Phase I/II trial (LIBRETTO-121) that supported FDA approval, Retevmo (selpercatinib) treatment was safe in pediatric patients of 2 years or older with solid tumors (8 medullary thyroid cancer, 2 papillary thyroid cancer, 1 osteosarcoma) harboring RET fusion (n=2) or mutations (n=9), and resulted in unconfirmed partial responses in 4 patients, stable disease in 6 patients (two lasting >/=16 weeks) (JCO 39, 10009-10009(2021); NCT03899792). detail... detail... detail...
RET mutant thyroid gland medullary carcinoma sensitive Selpercatinib Guideline Actionable Retevmo (selpercatinib) is included in guidelines for adult or pediatric patients 12 years or older with advanced medullary thyroid gland carcinoma harboring RET mutations (PMID: 31549998, PMID: 35491008; ESMO.org). 31549998 detail... 35491008
RET mutant thyroid gland medullary carcinoma sensitive Pralsetinib Guideline Actionable Gavreto (pralsetinib) is included in guidelines (category 2B) for patients with medullary thyroid carcinoma harboring RET mutations (NCCN.org). detail...
RET mutant thyroid gland medullary carcinoma sensitive Pralsetinib Guideline Actionable Gavreto (pralsetinib) is included in guidelines for adult or pediatric patients 12 years or older with advanced or metastatic medullary thyroid gland carcinoma harboring RET mutations (PMID: 31549998, PMID: 35491008; ESMO.org). 31549998 detail... 35491008
RET mutant thyroid gland medullary carcinoma sensitive Pralsetinib FDA approved Actionable In a Phase I/II trial (ARROW) that supported FDA approval, Gavreto (pralsetinib) treatment was well-tolerated and resulted in an overall response rate (ORR) of 60% (3/55) in patients with advanced or metastatic medullary thyroid cancer harboring RET mutations who received prior treatments, ORR was 60% (32/53) in patients with prior therapies and 71% (15/21) in treatment-naive patients (PMID: 34118198; NCT03037385). 34118198 detail...
RET mutant Advanced Solid Tumor predicted - sensitive EP0031 Phase Ib/II Actionable In a Phase I/II trial (KL400-I/II-01), EP0031 treatment was well tolerated and demonstrated preliminary activity in patients with advanced solid tumors harboring mutations in RET, resulting in an objective response rate of 64%, with responses being observed in patients with non-small cell lung cancer, medullary thyroid cancer and pancreatic cancer (J Clin Oncol 41, 2023 (suppl 16; abstr 3007); NCT05265091). detail...
RET mutant colorectal cancer sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) demonstrated efficacy in RET mutant positive colorectal cancer cell lines (PMID: 23811235). 23811235
RET mutant lung non-small cell carcinoma unknown unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a retrospective clinical study, patients with non-small cell lung cancer harboring rare targetable drivers (RTD) (BRAF, ERBB2/3, RET, MET, ROS1, NTRK) who received immune checkpoint inhibitors (ICI) achieved longer median overall survival (mOS) (32 vs 13 mo, p=0.01) compared to those who did not receive ICI, mOS was 44.9 mo in a patient harboring RET mutation, although RTD type was not associated with OS in a univariate analysis (PMID: 30268448). 30268448
RET mutant thyroid gland medullary carcinoma sensitive Everolimus Phase II Actionable In a Phase II trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, including patients harboring RET mutations, with median progression-free survival of 33 weeks (PMID: 26294908; NCT01118065). 26294908
RET mutant Advanced Solid Tumor sensitive Ponatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cancer cell lines harboring RET mutations in cultured and in cell line xenograft models (PMID: 23526464). 23526464
RET mutant pheochromocytoma predicted - sensitive Sunitinib Case Reports/Case Series Actionable In a Phase II trial (SNIPP), a patient with pheochromocytoma harboring a germline RET mutation achieved a partial response to treatment with Sutent (sunitinib), and demonstrated a 64% reduction in tumor volume and remained on treatment for over 7 years (PMID: 31105270). 31105270
RET mutant cancer sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited wild-type RET and RET mutations to prevent cell proliferation in cell culture (PMID: 17664273). 17664273
RET mutant thyroid gland medullary carcinoma sensitive Cabozantinib Phase III Actionable In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (60 vs 20 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET mutations (PMID: 27525386). 27525386
RET mutant lung non-small cell carcinoma predicted - sensitive EP0031 Phase Ib/II Actionable In a Phase I/II trial (KL400-I/II-01), EP0031 treatment was well tolerated in non-small cell lung cancer (NSCLC) patients harboring RET mutations, and resulted in an objective response rate (ORR) of 63% (20/32, 1 complete response (CR)) and disease control rate (DCR) of 91% in pretreated patients, and an ORR of 76% (19/25, 1 CR) and DCR of 92% with median duration of response not reached in treatment-naive patients, and an overall CNS DCR of 100% (J Clin Oncol 41, 2023 (suppl 16; abstr 3007); NCT05265091). detail...